EP 1,021B - Living with Silent Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease characterized by the accumulation of lipids in liver cells not associated with the consumption of alcohol. It causes cellular dysfunction and, in some people, leads to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. Estimates show that 357 million people will have NASH globally by 2030.

Because NASH symptoms are not obvious, it is often underdiagnosed and underreported. Federally Qualified Health Care (FQHC) centers and their staff of community-based healthcare providers play a critical role in meeting the primary healthcare needs of underserved populations and ensuring access to care. Part of the epidemiology of chronic diseases that are managed in the FQHC system also includes diabetes, hypertension, and obesity.

Dr. Robert Gish, Medical Director, Hepatitis B Foundation, WILL discuss the burden of these diseases and the importance of early detection for liver diseases like NAFLD and NASH in a community health center setting. To learn more about liver diseases, check out this podcast from NASHNET, a global network of thought leaders dedicated to innovating NASH care delivery.

Want better health and nutrition? Now you can get personalized supplement recommendations and custom vitamin packs delivered to your door! Go to PersonaNutrition.com/Roizen and take your free assessment and get 50% off your order today. - sponsor


Persona logo


 

Bonus
How Your Diet Affects Your Risk for Cancer



EP 1,021B - Living with Silent Liver Disease
Featuring:
Robert G. Gish, M.D.

In 2013, Dr. Robert Gish joined the consulting faculty at La Maestra in San Diego, California, to establish a liver care program in the Federally Qualified Health Care clinic. His integral role in the diagnosis, treatment and management of patients with NAFLD and NASH provides valuable guidance for this specialized sector of patient care.


An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has made invaluable contributions to the understanding and treatment of hepatitis B, which is the world’s leading cause of liver cancer. A longtime supporter of the foundation’s mission and a member of the Scientific Advisory Board, Dr. Gish’s role as Medical Director of the Hepatitis B Foundation will further strengthen its research and advocacy efforts worldwide.

After receiving his medical degree in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on the investigation of viral hepatitis B and C. He went on to become medical director of the liver transplant program at California Pacific Medical Center in 1994, developing an outreach program that eventually served more than 35,000 patients in northern California and Nevada and made the medical center a leading liver transplant center.

Over the course of his career, Dr. Gish has published more than 600 original articles, abstracts and book chapters and more than 120 peer-reviewed publications.